2024-07-15 15:37:04 ET
Summary
- CytomX Therapeutics develops innovative oncology treatments using its Probody platform, creating conditionally activated biologics that increase drug efficiency and reduce side effects.
- Strategic partnerships with leading companies like Amgen, Astellas, and Bristol Myers Squibb leverage CTMX's Probody platform for drug development.
- The pipeline includes early-stage drugs CX-904, CX-2051, and CX-801, with preclinical programs.
- CTMX has a short cash runway and potential dilution risks in the next few years.
- I ultimately rate CTMX a “hold” due to balanced positives and negatives, but I think it's worth adding to your watchlist.
...
Read the full article on Seeking Alpha
For further details see:
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments